Targets › TK
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on TK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The Methodist Hospital Research Institute | ADV/HSV-tk Adenoviral vector encoding herpes simplex virus thymidine kinase (HSV-tk) for suicide gene | TK | Phase 1 | Glioblastoma | Dec 2026 |
Glioblastoma (1)
other (1)
The Methodist Hospital Research Institute (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.